Clinical Compliance Programs: Investigator Payments, GCPs, and More…. Teri Crouse, J.D. Director of Compliance for Healthcare & Marketing.

Slides:



Advertisements
Similar presentations
4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.
Advertisements

Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
MSCG Training for Project Officers and Consultants: Project Officer and Consultant Roles in Supporting Successful Onsite Technical Assistance Visits.
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
SITUATION RESPONSE FLOW CHART SUPERVISORS’S ACTIONS SITUATION OCCURS Direct observation, complainant reports, third party reports Document initial knowledge.
Campus Improvement Plans
Environmental Management System (EMS)
1 District 7610 Rotary Foundation Seminar Grants ManagementSlide 1 Grants Management PDG Travis White District 7610 Rotary Foundation Stewardship Committee.
Quality Improvement/ Quality Assurance Amelia Broussard, PhD, RN, MPH Christopher Gibbs, JD, MPH.
Environmental Management System Bruce Barnard Terry Parish Teresa Woodley.
Sales & Marketing Compliance Training
Responsible Conduct of Research, Scholarship, and Creative Activities Peer Review Responsible Conduct of Research, Scholarship, and Creative Activities.
Principles of Marketing
Office of Inspector General (OIG) Internal Audit
Informed Consent and HIPAA Tim Noe Coordinating Center.
Training Module 6: Association Employees and Volunteers Presented by the Southern Early Childhood Association.
SEMINAR NAIC/ASSAL/SVS REGULATION & SUPERVISION OF MARKET CONDUCT © 2014 National Association of Insurance Commissioners Complaint Handling.
Welcome ISO9001:2000 Foundation Workshop.
Control environment and control activities. Day II Session III and IV.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
How many balls can you juggle at one time?. Identify 7 balls extension middle managers juggle every day in leading the extension program Identify strategies.
Marketing Research  Def. - Formal communication link with the environment to provide accurate and useful information for better decision making.  Systematic.
The role of ERE in Costumer Protection Eduard Elezi Albanian Regulatory Authority ERE Conference “Albanian Energy Sector, Challenges and Regulation” Tirana,
Basics of OHSAS Occupational Health & Safety Management System
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
OIG COMPLIANCE GUIDANCE FOR PHYSICIAN PRACTICES Washington County Hospital Association, Inc. CME Program October 26, 2000.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Purchasing Ethics and Vendor Relations
Conservation Districts Supervisor Accreditation Module 9: Employer/Employee Relations.
1 Ethics For the Employee Benefits Agent.  Ethics – defined as a principle of right or good conduct; a system of moral principles or values; the rules.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Unit 14: Developing a Corrective Action Program Unit Introduction and Overview Unit objectives:  The purpose of a CAP  How a CAP benefits and supports.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Pre-Conference Questions: Legal/Regulatory & Operational Considerations March 5, 2009.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Setting the Scene: The Role of Ethics and Compliance in the Biopharmaceutical Market.
Facilitate Group Learning
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress 1 How to Implement a Private Payer Reimbursement Strategy Barbara Grenell.
Is Your Background Check Process Compliant?. 2 © Copyright 2015 ADP, LLC. Proprietary and Confidential Information. Agenda Privileged & Confidential.
© BLR ® —Business & Legal Resources 1408 How to Manage Challenging Employees.
Welcome….!!! CORPORATE COMPLIANCE PROGRAM Presented by The Office of Corporate Integrity 1.
1Mobile Computing Systems © 2001 Carnegie Mellon University Writing a Successful NSF Proposal November 4, 2003 Website: nsf.gov.
South Region Compliance Seminar December 2-3, 2015 | New Orleans, LA Variable Annuities Procedures Practices and Findings.
Presented By WVDE Title I Staff June 10, Fiscal Issues Maintain an updated inventory list, including the following information: description of.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
Dr. Samuel Dyer - Chairman of the Board - Medical Science Liaison Society MSL What is a Medical Science Liaison? (What Do.
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
Evaluation Chapter 9. Chapter Objectives Learn: –How evaluation incorporates into the overall problem solving process. –Ethical considerations for solution.
1 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq.
Challenges in Promoting RCR: Reflections from a Public Funder´s Perspective Secretariat on Responsible Conduct of Research [Canadian Institutes of Health.
PATIENT & FAMILY RIGHTS AT DOHMS. Fully understand and practice all your rights. You will receive a written copy of these rights from the Reception, Registration.
©SHRM SHRM Speaker Title Bhavna Dave, PHR Director of Talent SHRM member since 2005 Session 2: Relationship Management Competencies for Early-Career.
GCP (GOOD CLINICAL PRACTISE)
Good Clinical Practice (GCP) and Monitoring Practices
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
MGMT 452 Corporate Social Responsibility
FDA’s IDE Decisions and Communications
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
Lilly Grant Funding Disclosure May 27, 2008
Developing an Effective Compliance Training Program for Pharmaceutical Sales Personnel Kelly B. Freeman, Ph.D. Director, US Affiliate, Compliance and.
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
Presentation transcript:

Clinical Compliance Programs: Investigator Payments, GCPs, and More…. Teri Crouse, J.D. Director of Compliance for Healthcare & Marketing

High Level Overview …And More OIG Guidance and Medical departments CME / ACCME Field-Based Medical Personnel Transparency and Firewalls OR How to achieve separation between commercialization and medical/scientific areas

Counseling Medical on OIG Compliance What is your client’s current perspective on compliance? Medical generally: GCP mentality, process/SOP focused OIG focus is INTENT: Not just what, but also why

“Intent” and “One Purpose” Question is intent: not impact, not amount, not whether legitimate service was rendered,… Kickback if any one purpose of offer is to induce … Grant ($) Pharma Company Healthcare Provider Purchase ($)

The standard of scrutiny “ There is no true intent, only perception of intent” Opportunities to establish perceptions of improper intent are numerous Example: Investigator-initiated grant program At initiation of request Prior to consideration During consideration When communicating decision During conduct of research

“Intent” and Investigator Payments Difficult to get Medical/Scientific areas to understand the “follow the money” mentality Fair Market Value What work is being performed? What is the value of the researcher’s time “on the market”? Are you hiring a world thought leader? A regional thought leader? Can this site / investigator speed up your trial? He / she has a large pool of potential patients He / she has a proven track record in conducting clinical research and following GCPs

“Intent” and off-label promotion Question of intent in medical research: Conduct and publish off-label studies to answer important scientific questions and disclose those answers to the medical community vs. Conduct and publish off-label studies to promote off-label use through investigators’ study experience and physicians hearing study results Question of intent in Medical Science Liaison role: MSLs provide special medical expertise in addressing HCP questions regarding company products vs. MSLs discuss company products with HCPs to promote off-label uses of company products

“Intent” and the For-Profit Pharma Company “But ultimately, isn’t everything we do designed to sell our products?” Intent vs. consequence General intent vs. specific intent

Ensuring Behaviors Align with a Valid Intent Exercise: – Clearly define the purpose of your activity, – Vigorously align your actions with that purpose – Challenge anything that creates contrary perceptions

Ensuring Behaviors Align with a Valid Intent Example: Investigator-initiated Grant Program Roles of Medical and Marketing –Funding source –Communications with requester –Consideration of request –Monitoring progress of research Valid decision-making –Criteria for decision-making –Application of criteria –Source of request –Amount of request Follow through –Structure of grant support –Monitoring progress

ACCME and CME Increasing concern over “control” by sponsors Reaction: increased stringency on conflict of interest rules Increased stringency toward role of sponsor in CME What is the future of Pharma-sponsored CME?

ACCME and CME Increasing concern over “control” by sponsors Reaction: increased stringency on conflict of interest rules Increased stringency toward role of sponsor in CME What is the future of Pharma-sponsored CME?

Confusion over Field-Based Personnel Sales reps vs. Medical Science Liaisons Promotional or not? Where to draw the line

Role of the Sales Representative To detail customers on your products To provide samples To provide customer service They are the face of your company to your customers - Being Responsive, but not always the Responder

Role of the Medical Science Liaison To interact with Thought Leader physicians To develop relationships with potential research physicians To help evaluate potential research physicians To answer questions (not to prompt questions!) To provide customer service They are also the face of your company to your customers - Being Responsive, but not always the Responder

A hypothetical situation A customer asks a sales rep if the company could provide funding for an upcoming regional medical society conference. Does the rep respond: A)Can you tell me how many other doctors on my call list will be there and will there be a presentation about my product? B)No problem doc, since you are such a big writer. C) You will have to submit a grant request to the appropriate department at my company. Here’s the information on how to submit your request.

A customer tells a sales rep she is considering doing a small study with your product and wants to know if she could get a research grant. A hypothetical situation Does the rep respond: A)I’ll check with my district manager. I think he has some extra money right now. B)Only if you’re going to purchase the product. C)Our medical department evaluates all research funding requests based on the scientific merit of the proposal. I can only provide you with the contact information for that department.

A customer asks your rep to do a literature search for information about one of the known side effects of your product. A hypothetical situation How does the rep respond: A)Runs to the university medical library and copies all the articles he can find. B)Tells the doctor not to worry about that side effect, it’s really not a big deal. C)Tells the doctor he will submit a request for your medical department to send the information they have related to the side effect.

While your rep is making a sales call on a customer who is being considered for participation as a clinical investigator, the customer complains that they have contacted the medical person at your company with a question, but haven’t received back a reply. A hypothetical situation How does the rep respond: A)Tell me your question, and I’ll contact the medical person again for you. B)Tell me your question, I can probably answer it for you. C)I will contact the medical person or their supervisor and ask them to get back with you as soon as possible.

How can you be certain that your sales reps would know that only answer C is appropriate in each of these hypothetical situations? And the answer is…. Implement a complete Compliance Program Compliance Program Policy & Procedures Training Communication Monitor & Audit Owner Discipline Process Corrective Actions

Policies and Procedures Develop policies and procedures for Sales and Marketing personnel and corresponding Medical department policies Grant requests ­ Educational ­ Research Medical information Interactions between Medical personnel and Sales and Marketing personnel

Training and Communication Explain the importance of the “firewall” between Medical and Sales / Marketing Clearly outline roles and responsibilities Train on Anti-Kickback law and the OIG guidance Cover how to handle “real world” situations in the proper manner – Use scenarios – Give verbatims – Model the appropriate behavior

Monitoring and Auditing Review district expenses Attend sales meetings Ride with reps Review call notes Audit grants

Corrective actions Provide a hotline for reporting violations Investigate any findings or reports Implement corrective actions –Discipline –Preventive measures

Summary In order to maintain the “firewall” between Sales & Marketing and Medical Personnel Develop clear policies and procedures Provide training on ”real world” scenarios Monitor to assure compliance Take corrective action, if necessary